Original InvestigationPathogenesis and Treatment of Kidney Disease and HypertensionIdentification and Referral of Patients With Progressive CKD: A National Study
Section snippets
Study Design
We conducted a national cross-sectional study of PCPs and nephrologists in the United States between August 2004 and August 2005 by using a self-administered mailed questionnaire designed to ascertain physicians’ approaches to the identification, evaluation, and referral of patients with NKF-KDOQI stages 3 (GFR, 30 to 59 mL/min/1.73 m2 [0.50 to 0.98 mL/s]) and 4 (GFR, 15 to 29 mL/min/1.73 m2 [0.25 to 0.48 mL/s]) CKD, a group at high risk for progression of CKD and associated morbidity. We
Response Rate, Scenario Randomization, and Physician Characteristics
Of 1,200 physicians initially targeted, 131 had moved, were no longer contactable, or had incorrect addresses; 52 were not PCPs or nephrologists; and 58 were dead or no longer practicing medicine (total, 241 ineligible physicians). Of the remaining 959 eligible physicians, 304 physicians responded (comprising 178 PCPs [89 family physicians and 89 general internists] and 126 nephrologists; 28% response rate for family physicians, 28% for general internists, 39% for nephrologists). There were no
Discussion
In this study of physicians sampled randomly from across the United States, our findings suggest that efforts to raise physicians’ awareness of progressive CKD and disseminate recently developed clinical practice guidelines have not been as effective as hoped.17, 18 Our findings highlight that PCPs and nephrologists have different perceptions of how the evaluation of patients with progressive CKD should be undertaken and the intensity with which specialists should be involved in their care.
References (40)
- et al.
Prevalence of chronic kidney disease and decreased kidney function in the adult US populationThird National Health and Nutrition Examination Survey
Am J Kidney Dis
(2003) - et al.
Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease
Kidney Int
(2001) - et al.
Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus
Am J Cardiol
(1997) - et al.
Moderate renal insufficiency and the risk of cardiovascular mortalityResults from the NHANES I
Kidney Int
(2002) - et al.
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertensionThe Captopril Prevention Project (CAPPP) randomised trial
Lancet
(1999) - et al.
Quality of prereferral care in patients with chronic renal insufficiency
Am J Kidney Dis
(2002) - et al.
Late referral to a nephrologist reduces access to renal transplantation
Am J Kidney Dis
(2003) - et al.
Executing change in the management of chronic kidney diseasePerspectives on guidelines and practice
Med Clin North Am
(2005) - et al.
Renal function preservation in type 2 diabetes mellitus patients with early nephropathyA comparative prospective cohort study between primary health care doctors and a nephrologist
Am J Kidney Dis
(2006) - et al.
CKD risk factors reported by primary care physiciansDo guidelines make a difference?
Am J Kidney Dis
(2006)
An evaluation of a shared primary and secondary care nephrology service for managing patients with moderate to advanced CKD
Am J Kidney Dis
Principles of appropriate antibiotic use for treatment of uncomplicated acute bronchitisBackground
Ann Emerg Med
Cystatin C and the risk of death and cardiovascular events among elderly persons
N Engl J Med
Cystatin C concentration as a risk factor for heart failure in older adults
Ann Intern Med
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
N Engl J Med
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosisA randomized controlled trial
JAMA
Risk of end-stage renal disease in diabetes mellitus: A prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial
JAMA
ACE inhibitors to prevent end-stage renal disease: When to start and why possibly never to stop: A post hoc analysis of the REIN trial resultsRamipril Efficacy in Nephropathy
J Am Soc Nephrol
The timing of specialist evaluation in chronic kidney disease and mortality
Ann Intern Med
Opportunities for improving the care of patients with chronic renal insufficiencyCurrent practice patterns
J Am Soc Nephrol
Cited by (178)
CKD Progression Prediction in a Diverse US Population: A Machine-Learning Model
2023, Kidney MedicineOvercoming Barriers to Implementing New Therapies for Diabetic Kidney Disease: Lessons Learned
2021, Advances in Chronic Kidney DiseaseCitation Excerpt :Physician surveys have indicated that 22%-30% of family physicians and general internist were aware of the existence of NKF-KDOQI. In contrast, approximately 80% of the same physician group were aware that the American Diabetes Association (ADA) and the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure guidelines influence CKD care.57,58 Providers are further disincentivized by system-level barriers such as insufficient time for managing a complicated chronic disease, limited reimbursement, inadequate clinical support, and lack of services and resources such as patient education materials and physician extenders to facilitate care (eg, diabetes care and education specialists, dietitians, clinical pharmacists).59
The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
2021, Kidney InternationalCitation Excerpt :Identifying high-risk individuals for CKD screening will require that clinicians are educated about CKD risk factors. Effective CKD risk stratification will require education about CKD staging, particularly the importance of albuminuria.48,49,96,97 To bridge the education gap, existing guidelines could be simplified with quick reference guides for primary care clinicians.
Knowledge Is Power: Patient Education as a Tool for Patient Activation
2020, American Journal of Kidney Diseases
Originally published online as doi:10.1053/j.ajkd.2006.04.073 on June 14, 2006.
Support: Funding sources are National Kidney Foundation of Maryland Mini-Grant (L.E.B.); Robert Wood Johnson Harold Amos Faculty Development Program (L.E.B.); Grant no. K240502643 from National Institute of Diabetes and Digestive and Kidney Diseases (N.R.P.). Potential conflicts of interest: None.